PRME Q3 2025 Earnings — Prime Medicine, Inc. Revenue & Financial Results | Market Cap Arena

PRMEPrime Medicine, Inc.

$771M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+486.1% YoY

Gross Profit

-$43M-3491.0% margin

Operating Income

-$54M-4406.0% margin

Net Income

-$51M-4129.1% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+9.9%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$385M

Total Liabilities

$223M

Stockholders' Equity

$162M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$209,000	+486.1%
Gross Profit	-$43M	$209,000	-20561.7%
Operating Income	-$54M	-$54M	+0.5%
Net Income	-$51M	-$53M	+3.7%

Revenue Segments

Reportable Segment

$1M100%